Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The conversation is about hair loss treatments, specifically discussing the use of dutasteride (DUT), minoxidil (Min), spironolactone, RU58841, and pyrilutamide. The user is considering increasing DUT dosage and exploring microneedling with topical treatments.

A 34-year-old male shares his hair regrowth journey using Minoxidil Max Dual Gen with topical finasteride, hair oil, derma rolling, and nizoral shampoo, emphasizing persistence and consistency. Despite some skepticism about lighting and treatment effectiveness, he reports significant progress over 12 months.

Microneedling at 0.6mm depth every two weeks showed better hair growth results than using minoxidil alone. Using a derma pen is recommended over a roller to avoid scarring.

The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.

The user experienced initial hair improvement with finasteride but noticed worsening hair loss after switching to dutasteride. They are considering returning to finasteride due to persistent hair shedding and scalp itch.

People have reported hair thickening with Pyrilutamide, particularly using a 1% concentration. Some users are curious about the availability of different concentrations like 0.9%.

Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.

Finasteride worked better for frontal scalp hair loss, while dutasteride helped the crown and mid-scalp but worsened the frontal area. The user shared personal experiences and invited open dialogue.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

The user is experiencing hair regrowth using finasteride, minoxidil, and KX-826. They regret not starting treatment earlier but are now seeing progress.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

A user on finasteride for 7 months is experiencing increased hair loss and is considering adding dutasteride or minoxidil to their regimen. They are seeking advice on whether to switch treatments or continue their current plan.

A dental technician claims malocclusion causes pattern hair loss due to poor scalp circulation. Users debate this, noting treatments like finasteride, minoxidil, and microneedling focus on DHT and blood flow.

Panax ginseng, specifically a ginsenoside-enriched formulation, is suggested as a potential hair growth treatment alongside finasteride and minoxidil. The user is considering trying panax ginseng despite limited availability and evidence.

The conversation is about using alfatradiol (17α-estradiol) as a hair loss treatment. The user is considering adding it to their regimen due to its safety and availability.

A young man faces severe hair loss in his early 20s, using treatments like dutasteride and minoxidil with little success, impacting his self-esteem and relationships. He considers hair systems and therapy as potential solutions.

The conversation is about seeking new research on hair loss treatments beyond the commonly known ones like Minoxidil and Finasteride. Additions to the list of treatments include topical caffeine, alfatradiol, fluridil, stemoxydine, and upcoming treatments like TDM-105795 and verteporfin.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.

The conversation discusses the idea of naturally lowering testosterone levels to potentially reduce DHT and help with hair loss, though it is speculative and not tested by the original poster. Participants suggest using treatments like finasteride, dutasteride, or RU58841 instead, as they directly target DHT without reducing testosterone.

Balding is challenging, and relying on medications like finasteride is often seen as a better option than constantly shaving or trying to compensate in other areas. Many feel that societal expectations to "own it" or drastically change oneself to cope with baldness are unrealistic and burdensome.

People are humorously discussing unconventional and satirical uses of minoxidil, such as drinking it or injecting it, and the potential absurd consequences. The conversation also touches on the ineffectiveness and risks of these methods compared to proper topical application with microneedling.

The conversation humorously suggests that drug use might be more effective for hair retention than traditional treatments like minoxidil or finasteride. It attributes full heads of hair in homeless individuals to lifestyle factors like reduced stress or hormonal changes.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

Using lice as an alternative to microneedling for hair loss treatment, with concerns about effectiveness and practicality. Some users humorously suggest genetically altering lice to produce beneficial compounds.

The user shared their experience with finasteride, noting initial side effects like weaker erections and anxiety, which improved over time as they recognized the nocebo effect. They emphasized that anxiety can amplify perceived side effects, and encouraged others to consider this when evaluating their own experiences with the medication.

The user is considering using tretinoin with topical finasteride due to poor absorption and side effects from oral finasteride. They are also contemplating switching to topical dutasteride, while others suggest trying oral minoxidil or lower oral doses.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.